The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells

Molecular and Cellular Biology

Volumn 34, Issue 4, 2014, Pages 739-751

  Razorenova, Olga V ^a,b   Castellini, Laura ^a   Colavitti, Renata ^a   Edgington, Laura E ^a   Nicolau, Monica ^a,c   Huang, Xin ^d   Bedogni, Barbara ^e   Mills, Edward M ^f   Bogyo, Matthew ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DNA STRUCTURE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE LOSS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; HYPOXIA RESPONSIVE ELEMENT; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SCID MOUSE;

AIDS-RELATED COMPLEX; ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84892959528     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00644-12     Document Type: Article

References (54)

1. Razorenova OV, Giaccia AJ. 2010. Hypoxia, gene expression, and metastasis, p 43-58. In Bagley RG (ed), The tumor microenvironment. Springer Science+Business Media, LLC, New York, NY.
2. Semenza GL. 2009. Regulation of oxygen homeostasis by hypoxiainducible factor 1. Physiology (Bethesda) 24:97-106. http://dx.doi.org/10 .1152/physiol.00045.2008.
3. Clark PE. 2009. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 76:939-945. http://dx.doi.org/10.1038/ki.2009.296.
4. Koseki T, Inohara N, Chen S, Nunez G. 1998. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. U. S. A. 95:5156-5160. http://dx.doi.org/10.1073/pnas.95.9.5156.
5. Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, Hayakawa Y, Lee P, Korsmeyer SJ, Kitsis RN. 2004. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol. Cell 15:901-912. http://dx.doi.org/10.1016/j.molcel.2004.08.020.
6. Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. 2004. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J. Biol. Chem. 279:21233-21238. http://dx.doi.org/10.1074/jbc.M400695200.
7. Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, Kitsis RN. 2005. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiationresistance. Cell Death Differ. 12:682-686. http://dx.doi.org/10.1038/sj.cdd.4401631.
8. Wang M, Qanungo S, Crow MT, Watanabe M, Nieminen AL. 2005. Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei. FEBS Lett. 579:2411-2415. http://dx.doi.org/10.1016/j.febslet.2005.03.040.
9. Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD, Hersey P. 2008. Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein. Cancer Res. 68:834-842. http://dx.doi.org/10.1158/0008-5472.CAN-07-5056.
10. Wang JX, Li Q, Li PF. 2009. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1. Cancer Res. 69:492-500. http://dx.doi.org/10.1158/0008-5472.CAN-08-2962.
11. Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, Ferrick N, Segall J, Pollard JW, Kitsis RN. 2011. Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer Res. 71:7705-7715. http://dx.doi.org/10.1158/0008-5472.CAN-11 -2192.
12. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. 2011. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117:780-787. http://dx.doi.org/10.1182/blood-2010-04-280503.
13. Foo RS, Nam YJ, Ostreicher MJ, Metzl MD, Whelan RS, Peng CF, Ashton AW, Fu W, Mani K, Chin SF, Provenzano E, Ellis I, Figg N, Pinder S, Bennett MR, Caldas C, Kitsis RN. 2007. Regulation of p53 tetramerization and nuclear export by ARC. Proc. Natl. Acad. Sci. U. S. A. 104:20826-20831. http://dx.doi.org/10.1073/pnas.0710017104.
14. Neuss M, Monticone R, Lundberg MS, Chesley AT, Fleck E, Crow MT. 2001. The apoptotic regulatory protein ARC (apoptosis repressor with caspase recruitment domain) prevents oxidant stress-mediated cell death by preserving mitochondrial function. J. Biol. Chem. 276:33915-33922. http://dx.doi.org/10.1074/jbc.M104080200.
15. Nam YJ, Mani K, Wu L, Peng CF, Calvert JW, Foo RS, Krishnamurthy B, Miao W, Ashton AW, Lefer DJ, Kitsis RN. 2007. The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli: identification of a degradation-resistant mutant. J. Biol. Chem. 282:5522-5528. http://dx.doi.org/10.1074/jbc.M609186200.
16. Foo RS, Chan LK, Kitsis RN, Bennett MR. 2007. Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2. J. Biol. Chem. 282:5529-5535. http://dx.doi.org/10.1074/jbc.M609046200.
17. Li YZ, Lu DY, Tan WQ, Wang JX, Li PF. 2008. p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol. Cell. Biol. 28:564-574. http://dx.doi.org/10.1128/MCB.00738-07.
18. Wu L, Nam YJ, Kung G, Crow MT, Kitsis RN. 2010. Induction of the apoptosis inhibitor ARC by Ras in human cancers. J. Biol. Chem. 285: 19235-19245. http://dx.doi.org/10.1074/jbc.M110.114892.
19. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel- Lindau protein. Cancer Cell 1:237-246. http://dx.doi.org/10.1016/S1535-6108(02)00043-0.
20. Yan Q, Bartz S, Mao M, Li L, Kaelin WG, Jr. 2007. The hypoxiainducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol. Cell Biol. 27:2092-2102. http://dx.doi.org/10.1128/MCB.01514-06.
21. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, Broome-Powell M, Giaccia AJ. 2011. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}- driven migration. Proc. Natl. Acad. Sci. U. S. A. 108:1931-1936. http://dx.doi.org/10.1073/pnas.1011777108.
22. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. 2010. Regulation of the histone demethylase JMJD1A by hypoxiainducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol. 30:344-353. http://dx.doi.org/10.1128/MCB.00444-09.
23. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. 2011. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117:e207- e217. http://dx.doi.org/10.1182/blood-2010-10-314427.
24. Razorenova OV, Ivanov AV, Budanov AV, Chumakov PM. 2005. Virusbased reporter systems for monitoring transcriptional activity of hypoxiainducible factor 1. Gene 350:89-98. http://dx.doi.org/10.1016/j.gene.2005.02.006.
25. Higgins JP, Wang L, Kambham N, Montgomery K, Mason V, Vogelmann SU, Lemley KV, Brown PO, Brooks JD, van de Rijn M. 2004. Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol. Biol. Cell 15:649-656. http://dx.doi.org /10.1091/mbc.E03-06-0432.
26. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. 2006. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3:e13. http://dx.doi.org/10.1371/journal.pmed.0030013.
27. Nicolau M, Tibshirani R, Borresen-Dale AL, Jeffrey SS. 2007. Diseasespecific genomic analysis: identifying the signature of pathologic biology. Bioinformatics 23:957-965. http://dx.doi.org/10.1093/bioinformatics /btm033.
28. Edgington LE, van Raam BJ, Verdoes M, Wierschem C, Salvesen GS, Bogyo M. 2012. An optimized activity-based probe for the study of caspase-6 activation. Chem. Biol. 19:340-352. http://dx.doi.org/10.1016/j.chembiol.2011.12.021.
29. An J, Fisher M, Rettig MB. 2005. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene 24:1563-1570. http://dx.doi.org/10.1038/sj.onc.1208348.
30. Haase VH. 2006. Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol. 291:F271-281. http://dx.doi.org/10.1152/ajprenal.00071.2006.
31. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Jr, Signoretti S. 2009. Patterns of gene expression and copy-number alterations in von-Hippel Lindau diseaseassociated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69:4674-4681. http://dx.doi.org/10.1158/0008-5472.CAN-09-0146.
32. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. 2007. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin. Cancer Res. 13:4740-4749. http://dx.doi.org/10.1158/1078-0432.CCR-07-0143.
33. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. 2003. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 3:31. http://dx.doi.org/10.1186/1471-2407-3-31.
34. Potter C, Harris AL. 2004. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164-167. http://dx.doi.org/10.4161/cc.3.2.618.
35. Ludwig-Galezowska AH, Flanagan L, Rehm M. 2011. Apoptosis repressor with caspase recruitment domain, a multifunctional modulator of cell death. J. Cell. Mol. Med. 15:1044-1053. http://dx.doi.org/10.1111/j.1582-4934.2010.01221.x.
36. Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. 2013. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest. New Drugs 31:1436- 1443. http://dx.doi.org/10.1007/s10637-013-0017-x.
37. Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hulsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. 2013. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol. Cancer Ther. 12: 2459-2471. http://dx.doi.org/10.1158/1535-7163.MCT-13-0318.
38. Juengel E, Makarevic J, Tsaur I, Bartsch G, Nelson K, Haferkamp A, Blaheta RA. 2013. Resistance after chronic application of the HDACinhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One 8:e53100. http://dx.doi.org/10.1371/journal.pone.0053100.
39. Ao JE, Kuang LH, Zhou Y, Zhao R, Yang CM. 2012. Hypoxia-inducible Factor 1 regulated ARC expression mediated hypoxia induced inactivation of the intrinsic death pathway in p53 deficient human colon cancer cells. Biochem. Biophys. Res. Commun. 420:913-917. http://dx.doi.org/10.1016/j.bbrc.2012.03.101.
40. Hockel M, Schlenger K, Knoop C, Vaupel P. 1991. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 51:6098-6102.
41. Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC, III, Nunez G. 1999. ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ. Res. 85:e70-e77. http://dx.doi.org/10.1161/01.RES.85.12.e70.
42. Gustafsson AB, Sayen MR, Williams SD, Crow MT, Gottlieb RA. 2002. TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective. Circulation 106: 735-739. http://dx.doi.org/10.1161/01.CIR.0000023943.50821.F7.
43. Zhang YQ, Herman B. 2008. Expression and modification of ARC (apoptosis repressor with a CARD domain) is distinctly regulated by oxidative stress in cancer cells. J. Cell Biochem. 104:818-825. http://dx.doi.org/10.1002/jcb.21666.
44. Zaiman AL, Damico R, Thoms-Chesley A, Files DC, Kesari P, Johnston L, Swaim M, Mozammel S, Myers AC, Halushka M, El-Haddad H, Shimoda LA, Peng CF, Hassoun PM, Champion HC, Kitsis RN, Crow MT. 2011. A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension. Circulation 124:2533-2542. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.034512.
45. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91. http://dx.doi.org/10.1038/379088a0.
46. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. 2003. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1:e83. http://dx.doi.org/10.1371/journal.pbio.0000083.
47. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. 2012. State of the science: an update on renal cell carcinoma. Mol. Cancer Res. 10:859-880. http://dx.doi.org/10.1158/1541-7786.MCR-12-0117.
48. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. 2008. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14:435- 446. http://dx.doi.org/10.1016/j.ccr.2008.10.016.
49. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28:622-629. http://dx.doi.org/10.1002/humu.20495.
50. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. 2010. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140:384-396. http://dx.doi.org/10.1016/j.cell.2009.12.032.
51. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV. 2005. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc. Natl. Acad. Sci. U. S. A. 102:17448-17453. http://dx.doi.org/10.1073/pnas.0508888102.
52. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. 2004. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 64:1951-1958. http://dx.doi.org/10.1158/0008-5472.CAN-03-1541.
53. Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT. 2005. p53 regulation and function in renal cell carcinoma. Cancer Res. 65:6498-6503. http://dx.doi.org/10.1158/0008-5472.CAN-05-0017.
54. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. 2009. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 69:9056-9064. http://dx.doi.org/10.1158/0008-5472.CAN-09-1770.